Testing Tirzepatide After Gastric Bypass

On September 8, 2026, a team led by Jason Samuels at Vanderbilt University Medical Center published the rationale, design and baseline characteristics of a small trial testing whether tirzepatide helps patients whose obesity comes back, or never fully goes away, after gastric bypass surgery^[1]. The trial, registered as GRABS (GLP-1 Receptor Agonists Post-Bariatric Surgery), enrolled 28 adults who were on average more than a year past their surgery and still had a body mass index of 36.0, down from a pre-surgery average of 48.3^[1].

What the trial is testing

GRABS is a randomized, open-label pilot trial run out of Vanderbilt^[2]. Adults who are at least a year removed from a Roux-en-Y gastric bypass and still have a BMI above 30 are assigned either to tirzepatide or to standard post-surgical dietary care for 24 weeks. The trial tracks two things over that period: the change in body weight, and a validated gastrointestinal symptom score called PAGI-SYM, which covers nausea, bloating and related side effects that matter a great deal to people who have already had one abdominal surgery^[2].

The tirzepatide arm follows the same titration the FDA label specifies: dosing starts at 2.5 mg once weekly and rises by 2.5 mg every four weeks to a maximum of 15 mg, with room to slow the increase if gastrointestinal side effects are hard to tolerate^[4]. Participants assigned to standard care first are not left without an option later. After 24 weeks of dietary guidance from the Vanderbilt Surgical Weight Loss handbook, they cross over to the same tirzepatide protocol for a further 24 weeks^[2].

Why persistent obesity after bypass needed its own trial

Gastric bypass is still the most effective weight-loss intervention available, but it does not work forever for everyone. The trial's own registration materials cite an estimate that 65% of people experience persistent obesity after surgical weight loss alone^[2]. A separate peer-reviewed registry study of more than 2,000 Swedish patients found that 23.1% met at least one definition of surgical treatment failure five years after Roux-en-Y gastric bypass, whether measured by insufficient excess-weight loss, insufficient total weight loss, or a BMI that stayed above 35 or 40^[3].

Surgeons have had few structured options for that group. Revisional surgery carries its own risks, and until GLP-1 receptor agonists such as tirzepatide and semaglutide matured into weight-management drugs in their own right, there was no pharmacological add-on with trial evidence behind it. GRABS is built to start filling that specific gap: not obesity in general, but obesity that has already been through bypass surgery and has not gone away.

Who is eligible, and who is not

Enrollment runs to adults aged 25 to 65 who are at least 12 months out from a primary Roux-en-Y gastric bypass and have a BMI above 30^[2]. The published cohort was 82% female with a median age of 42, which tracks who gets bypass surgery in the first place^[1].

The exclusion list follows the same safety logic as tirzepatide's own label. People with type 1 diabetes, a recent history of GLP-1 receptor agonist use, an HbA1c above 8.5%, a history of pancreatitis, or a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are excluded from the trial^[2]. That last exclusion mirrors the boxed warning on tirzepatide's prescribing information, which flags thyroid C-cell tumors seen in rats and lists medullary thyroid carcinoma and MEN 2 as contraindications while human relevance remains undetermined^[4].

What GRABS does not show yet

This is a rationale-and-design paper, not a results paper. It reports who enrolled and how the trial is built, not how much weight anyone lost. GRABS is listed as active but not recruiting, with a primary completion date set for January 2027^[2]. At around 28 to 30 participants, it is sized as a pilot: large enough to test feasibility and estimate an effect, not large enough to settle the question the way a multi-hundred-patient phase 3 trial would.

That distinction matters for how readers should treat any early attention the trial gets. A rationale-and-design publication establishes that the study is real, approved and running as described. It says nothing yet about whether tirzepatide actually helps this specific group more than standard post-surgical care, or by how much.

Why this matters

The GLP-1 receptor agonist class already has strong data in people who have never had bariatric surgery. What has been missing is a trial-grade answer for the growing number of people living with both a surgical history and obesity that surgery did not resolve, a group current guidelines mostly leave to case-by-case judgment. When GRABS reports its weight and symptom outcomes, expected around its January 2027 primary completion date^[2], it will be one of the first randomized looks at exactly that scenario, rather than an extrapolation from trials that excluded post-surgical patients.

If you have had bariatric surgery and are weighing a GLP-1 medication afterward, the specifics of your surgery, your current health and your medication history all matter. That conversation belongs with the surgical or endocrinology team that knows your case. You can read how tirzepatide is regulated and labeled more broadly on our tirzepatide page.